Ordering
Available Variants10 mg
CHA.64444-10mg
Price
€106.40
Available – Dispatch in 14 days
50 mg
CHA.64444-50mg
Price
€331.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.64444-10mg | €106.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.64444-50mg | €331.20 |
≥98% (HPLC), powder, Estrogen receptor antagonist
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C26H29NO2 |
|---|---|
| CAS Number | 68392-35-8 |
| Molecular Weight | 387.51 |
| UNSPSC Code | 51111800 |
| PubChem Substance ID | 24895736 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 300 |
| Storage condition | desiccated, protect from light |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 + H312 + H332,H315,H319,H361fd |
| pcodes | P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P308 + P313 |
| Hazard Classifications | Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 |
| Storage Class | 11 - Combustible Solids |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
4-Hydroxytamoxifen, with the chemical identifier CAS: 68392-35-8, is a metabolite of the selective estrogen receptor modulator tamoxifen. It is known for its potent anti-estrogenic effects, particularly in breast tissue, which makes it a significant compound in the study and treatment of hormone receptor-positive breast cancer. The compound acts by competitively binding to estrogen receptors, thereby inhibiting the action of estrogen on breast cancer cells. This mechanism of action is crucial for its therapeutic application, as it can help in reducing the growth and proliferation of cancer cells that are dependent on estrogen for their growth. Research into 4-Hydroxytamoxifen continues to uncover its potential in oncology, highlighting its importance in the development of targeted therapies for breast cancer treatment. Its biochemical properties and pharmacological effects are areas of ongoing scientific investigation.
